Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

SARS-CoV-2 Virus: early-phase trial registry

2 of 3 indexed SARS-CoV-2 Virus trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count

SARS-CoV-2 Virus: 3 US clinical trials tracked, 2 recruiting.

SARS-CoV-2 Virus is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is The Geneva Foundation, running 2 of these trials.

Enrollment posture brief

Registry condition sars-cov-2-virus

OPEN 2 | RECR 67% | LATE 0 | EARLY 1 | RANK #5209 | SPON 2

Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%SARS-CoV-2 Virus (this)67%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near SARS-CoV-2 Virus

SARS-CoV-2 Virus lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for SARS-CoV-2 Virus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. SARS-CoV-2 Virus is recruiting above its size-band peers.

    2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on SARS-CoV-2 Virus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope Device
1 trials
A&M Breathalyzer PROTECT Kiosk Device
1 trials
Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose Biological
1 trials
Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose Biological
1 trials
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose Biological
1 trials
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose Biological
1 trials
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose Biological
1 trials

US sites by state

Facility locations filed on SARS-CoV-2 Virus trials. A trial with sites in several states counts in each.

Texas 2 trials
California 1 trials
Arizona 1 trials
Arkansas 1 trials
Alabama 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this SARS-CoV-2 Virus page

3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This SARS-CoV-2 Virus condition card totals 3 registered trials; most-linked intervention imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.